Department of Otolaryngology - Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Immunotherapy. 2020 Feb;12(2):111-121. doi: 10.2217/imt-2019-0191. Epub 2020 Feb 20.
Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various inflammatory biomarkers has led to the development of monoclonal antibodies that target the underlying mechanisms of inflammation. Dupilumab, which targets IL-4 and IL-13 signaling, serves as a novel agent for CRSwNP treatment. Three clinical trials, NCT01920893, and , have shown that dupilumab improves both subjective patient-reported outcomes and objective physician-evaluated metrics for CRSwNP. The favorable findings have resulted in approval by the US FDA in June 2019 as the first biologic therapy for CRSwNP.
伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）给医疗保健带来了重大挑战，导致患者生活质量下降，疾病管理所需资源利用的成本增加。对 CRSwNP 病理生理学的认识不断发展，各种炎症生物标志物的鉴定导致了靶向炎症潜在机制的单克隆抗体的发展。靶向 IL-4 和 IL-13 信号的度普利尤单抗是 CRSwNP 治疗的一种新型药物。三项临床试验（NCT01920893、 和 ）表明，度普利尤单抗可改善 CRSwNP 的主观患者报告结果和客观医生评估指标。这些有利的发现促使美国 FDA 于 2019 年 6 月批准度普利尤单抗成为首个用于 CRSwNP 的生物疗法。
